tradingkey.logo

Sangamo to reclaim hemophilia A therapy rights post Pfizer termination

ReutersDec 30, 2024 9:27 PM

- Sangamo Therapeutics SGMO.O said on Monday it would regain full rights to its hemophilia A gene therapy after co-development partner Pfizer PFE.N terminated the agreement.

(Reporting by Puyaan Singh in Bengaluru; Editing by Mohammed Safi Shamsi)

((Puyaan.Singh@thomsonreuters.com;))

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

Tradingkey
KeyAI